State Street SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) have delivered strong returns of 40.80% and 33.95% respectively over the trailing year, but their equal-weight versus market ...

A major biotech company is leaving the Bay Area. Pfizer is abandoning its research site at 181 Oyster Point Blvd. in South San Francisco. The biotech company will move out of the building by the end ...

CRISPR Therapeutics is the second largest holding in Cathie Wood's Ark Innovation ETF. Incoming clinical trial data could send the stock soaring this year. Growing sales of Casgevy plus new candidates ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...

Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn. “The past few ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...